参考文献/References:
[1] Writing Committee M,Ommen SR,Ho CY,et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy:A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2024,83(23):2324- 2405.
[2] Maron BJ,Rowin EJ,Maron MS,et al. Nonobstructive hypertrophic cardiomyopathy out of the shadows:known from the beginning but largely ignored ... until now[J]. Am J Med,2017,130(2):119-123.
[3] Argirò A,Zampieri M,Marchi A,et al. Stage-specific therapy for hypertrophic cardiomyopathy[J]. Eur Heart J Suppl,2023,25(suppl C):C155-C161.
[4] Rowin EJ,Maron BJ,Kiernan MS,et al. Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy:under-recognized subset of candidates for heart transplant[J]. Circ Heart Fail,2014,7(6):967-975.
[5] Olivotto I,Cecchi F,Poggesi C,et al. Patterns of disease progression in hypertrophic cardiomyopathy:an individualized approach to clinical staging[J]. Circ Heart Fail,2012,5(4):535-546.
[6] Maron BJ,Rowin EJ,Maron MS. Hypertrophic cardiomyopathy:new concepts and therapies[J]. Annu Rev Med,2022,73:363-375.
[7] Palmisano V,Cossa S,Esposito A,et al. Obstructive and nonobstructive hypertrophic cardiomyopathy:differences in global and segmental myocardial strain by cardiac magnetic resonance feature tracking[J]. J Thorac Imaging,2022,37(1):49-57.
[8] Bravo PE,Pinheiro A,Higuchi T,et al. PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy[J]. J Nucl Med,2012,53(3):407-414.
[9] Pozios I,Corona-Villalobos C,Sorensen LL,et al. Comparison of outcomes in patients with nonobstructive,labile-obstructive,and chronically obstructive hypertrophic cardiomyopathy[J]. Am J Cardiol,2015,116(6):938-944.
[10] Pelliccia F,Pasceri V,Limongelli G,et al. Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy:a systematic review and meta-analysis[J]. Int J Cardiol,2017,243:379- 384.
[11] 蔡晓琪,谢良地. 非二氢吡啶类钙拮抗剂的特殊临床应用[J]. 中华高血压杂志,2018,26(11):1008-1010.
[12] 国家心血管病中心心肌病专科联盟,中国医疗保健国际交流促进会心血管病精准医学分会“中国成人肥厚型心肌病诊断与治疗指南2023”专家组,宋雷,等.中国成人肥厚型心肌病诊断与治疗指南2023[J]. 中国循环杂志,2023,38(1):1-33.
[13] Zeppenfeld K,Tfelt-Hansen J,de Riva M,et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. Eur Heart J,2022,43(40):3997-4126.
[14] Green EM,Wakimoto H,Anderson RL,et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice[J]. Science,2016,351(6273):617-621.
[15] Maron BJ,Rowin EJ,Maron MS. Is regression of left ventricular hypertrophy really a good thing for patients with hypertrophic cardiomyopathy?:the emerging mavacamten story[J]. Am J Cardiol,2021,147:145-146.
[16] Ho CY,Mealiffe ME,Bach RG,et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2020,75(21):2649-2660.
[17] Spertus JA,Fine JT,Elliott P,et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy(EXPLORER-HCM):health status analysis of a randomised, double-blind, placebo-controlled,phase 3 trial[J]. Lancet,2021,397(10293):2467-2475.
[18] Maron MS,Masri A,Choudhury L,et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2023,81(1):34-45.
[19] Chuang C,Collibee S,Ashcraft L,et al. Discovery of aficamten(CK-274),a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy[J]. J Med Chem,2021,64(19):14142-14152.
[20] Mozzini C,Pagani M. The heart failure knights[J]. Curr Probl Cardiol,2023,48(9):101834.
[21] Maron MS,Mahmod M,Abd Samat AH,et al. Safety and efficacy of metabolic modulation with ninerafaxstat in patients with nonobstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2024,83(21):2037-2048.
[22] Poddar A,Murugesan KB,Padmanabhan C. Extended septal myectomy using a combined trans-aortic and apical approach for long basal and mid-cavity hypertrophic cardiomyopathy[J]. Indian J Thorac Cardiovasc Surg,2022,38(6):651-655.
[23] Ommen SR,Ho CY,Asif IM,et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy:A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines[J]. Circulation,2024,149(23):e1239-e1311.
[24] Nguyen A,Schaff HV,Nishimura RA,et al. Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure[J]. J Thorac Cardiovasc Surg,2020,159(1):145-152.
[25] Zeng J,Shu Q,Lu C,et al. The use of MitraClip for nonobstructive hypertrophic cardiomyopathy with mixed severe mitral valve regurgitation[J]. ESC Heart Fail,2023,10(2):1454-1460.
[26] Andrade JG,Turgeon RD,Macle L,et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation[J]. Eur Cardiol,2022,17:e10.
[27] Ommen SR,Mital S,Burke MA,et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation,2020,142(25):e558-e631.
[28] Akta? MK,Younis A,Saxena S,et al. Age and the risk of ventricular tachyarrhythmia in patients with an implantable cardioverter-defibrillator[J]. JACC Clin Electrophysiol,2023,9(7 Pt 1):979-988.
[29] Ponikowski P,Voors AA,Anker SD,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA) of the ESC[J]. Eur Heart J,2016,37(27):2129-2200.
[30] Pasqualucci D,Fornaro A,Castelli G,et al. Clinical spectrum,therapeutic options,and outcome of advanced heart failure in hypertrophic cardiomyopathy[J]. Circ Heart Fail,2015,8(6):1014-1021.
[31] Adler A,Fourey D,Weissler-Snir A,et al. Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients[J]. J Am Heart Assoc,2017,6(6):e005152.
[32] Basu J,Finocchiaro G,Jayakumar S,et al. Impact of exercise on outcomes and phenotypic expression in athletes with nonobstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2022,80(15):1498-1500.
[33] Lampert R,Ackerman MJ,Marino BS,et al. Vigorous exercise in patients with hypertrophic cardiomyopathy[J]. JAMA Cardiol,2023,8(6):595-605.
[34] 许浩博,王娟,张海鹏,等. 不同程度阻塞性睡眠呼吸暂停对非梗阻性肥厚型心肌病患者临床特征的影响[J]. 中国循环杂志,2021,36(6):579-585.
相似文献/References:
[1]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in
Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(5):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[2]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(5):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[3]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(5):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[4]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(5):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[5]尚依一 刘罗 庞明杰 张艳.基因检测在肥厚型心肌病中的应用进展[J].心血管病学进展,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
SHANG Yiyi,LIU Luo,PANG Mingjie,et al.Gene Detection for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(5):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
[6]王娟 杨艳敏.肥厚型心肌病发生缺血性卒中的危险因素和管理策略研究进展[J].心血管病学进展,2021,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
WANG Juan,YANG Yanmin.Risk Factors and Management Strategies of Ischemic Stroke in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(5):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
[7]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(5):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
[8]蓝庆肃 武锋超 马兰虎 韩冰 徐金 彭瑜 张钲.Mavacamten治疗肥厚型心肌病的研究进展[J].心血管病学进展,2021,(11):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
LAN Qingsu,WU Fengchao,MA Lanhu,et al.Mavacamten in Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(5):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[9]李传伟,罗浩,曾春雨.肥厚型心肌病室间隔消减策略的研究进展[J].心血管病学进展,2022,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
LI Chuanwei,LUO Hao,ZENG Chunyu.Septal Reduction Therapy of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(5):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
[10]李珂 赵海娟 赵耀 黄松群 郭志福.肥厚型心肌病合并心房颤动的导管消融[J].心血管病学进展,2022,(5):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
LI Ke,ZHAO Haijuan,ZHAO Yao,et al.Catheter Ablation of Hypertrophic Cardiomyopathy with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(5):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]